A number of research firms have changed their ratings and price targets for Bicara Therapeutics (NASDAQ: BCAX):
- 5/16/2026 – Bicara Therapeutics was downgraded by Wall Street Zen from “sell” to “strong sell”.
- 5/12/2026 – Bicara Therapeutics had its price target raised by Morgan Stanley from $36.00 to $37.00. They now have an “overweight” rating on the stock.
- 5/12/2026 – Bicara Therapeutics had its price target raised by The Goldman Sachs Group, Inc. from $16.00 to $18.00. They now have a “neutral” rating on the stock.
- 5/11/2026 – Bicara Therapeutics is now covered by Guggenheim. They set a “buy” rating and a $42.00 price target on the stock.
- 5/10/2026 – Bicara Therapeutics was upgraded by Guggenheim to “strong-buy”.
- 4/8/2026 – Bicara Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 3/31/2026 – Bicara Therapeutics had its price target raised by The Goldman Sachs Group, Inc. from $14.00 to $16.00. They now have a “neutral” rating on the stock.
- 3/31/2026 – Bicara Therapeutics had its price target raised by Wells Fargo & Company from $11.00 to $16.00. They now have an “equal weight” rating on the stock.
- 3/31/2026 – Bicara Therapeutics had its “outperform” rating reaffirmed by Wedbush. They now have a $30.00 price target on the stock.
- 3/31/2026 – Bicara Therapeutics had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $31.00 price target on the stock.
- 3/31/2026 – Bicara Therapeutics had its price target raised by HC Wainwright from $40.00 to $42.00. They now have a “buy” rating on the stock.
- 3/25/2026 – Bicara Therapeutics is now covered by Bank of America Corporation. They set a “buy” rating and a $35.00 price target on the stock.
Insider Buying and Selling
In other news, CFO Ivan Hyep sold 13,555 shares of Bicara Therapeutics stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $18.22, for a total transaction of $246,972.10. Following the sale, the chief financial officer owned 145,355 shares in the company, valued at $2,648,368.10. This trade represents a 8.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Claire Mazumdar sold 36,766 shares of the firm’s stock in a transaction on Monday, March 9th. The shares were sold at an average price of $19.17, for a total transaction of $704,804.22. Following the sale, the chief executive officer directly owned 339,392 shares of the company’s stock, valued at approximately $6,506,144.64. The trade was a 9.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 174,310 shares of company stock worth $3,459,283 in the last 90 days.
The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.
Further Reading
- Five stocks we like better than Bicara Therapeutics
- Consumer-Driven Stocks Boost Buybacks, Including Visa’s $20B Plan
- Iran Ceasefire Trade: 3 Energy Stocks to Own if Oil Falls to $80
- Willing and Abel: Berkshire’s New CEO Makes Huge Portfolio Changes in Q1
- Insider Buying Says Upstart Isn’t Down for the Count
Receive News & Ratings for Bicara Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
